<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857645</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-DACORAL-DLI</org_study_id>
    <nct_id>NCT04857645</nct_id>
  </id_info>
  <brief_title>ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients</brief_title>
  <official_title>A Phase II Prospective Study &quot;GFM-DACORAL-DLI&quot; ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of early administration of ASTX727 associated with late Donor Lymphocyte Infusions&#xD;
      after allogenic stem cell transplantation in very high risk MDS or AML patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective study of early administration of ASTX727 associated with late Donor Lymphocyte&#xD;
      Infusions after allogenic stem cell transplantation in very high risk MDS or AML patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free Survival (DFS) at one year post transplant</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Measure of time during which no sign of progression is found</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) at one year post transplant</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Measure of time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) at two years post transplant</measure>
    <time_frame>2 years post transplant</time_frame>
    <description>Measure of time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for DFS, OS and non-relapse mortality at 1 and 2 years</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Statistical study of cumulative incidence curves</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>MDS</condition>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>ASTX727 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX727</intervention_name>
    <description>Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation</description>
    <arm_group_label>ASTX727 treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Donor Lymphocyte Infusions</intervention_name>
    <description>In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles</description>
    <arm_group_label>ASTX727 treatment</arm_group_label>
    <other_name>DLI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged from 18 to 70 years&#xD;
&#xD;
          -  MDS or AML with unfavorable genetics defined as follow:&#xD;
&#xD;
          -  4 or more cytogenetic abnormalities or&#xD;
&#xD;
          -  3 cytogenetic abnormalities and TP53 or other unfavorable mutations (ASXL1, RUNX1) or&#xD;
&#xD;
          -  3 cytogenetic abnormalities and monosomal karyotype or&#xD;
&#xD;
          -  mutations involving EVI1&#xD;
&#xD;
          -  AML patients should have received chemotherapy&#xD;
&#xD;
          -  Marrow blast &lt; 20% for MDS and &lt; 10% for AML post chemotherapy&#xD;
&#xD;
          -  For MDS : Revised IPSS poor or very poor ; For AML : ELN adverse risk&#xD;
&#xD;
          -  Non-proliferative disease&#xD;
&#xD;
          -  A donor is available (HLA matched or mismatched)&#xD;
&#xD;
          -  Adequate contraception in women &lt; 50 years and for men. Subjects must agree to use,&#xD;
             and to be able to comply with, effective contraception without interruption, at least&#xD;
             the first six months after transplant, throughout the entire duration of study drug&#xD;
             therapy and for at least 6 months for women and 3 months for men after the last dose&#xD;
             of study drug therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ECOG 3 or more&#xD;
&#xD;
          -  Cancer less than 2 years before inclusion or cancer not in remission the last 2 years&#xD;
             before inclusion (except in situ cancer or baso cellular cancer)&#xD;
&#xD;
          -  Cardiac failure with Ejection Fraction &lt; 50%&#xD;
&#xD;
          -  Creatininemia level &gt; 150 µmol/L&#xD;
&#xD;
          -  Liver enzyme &gt; 3 N&#xD;
&#xD;
          -  Conjugated bilirubinemia &gt; 25 µmol/L&#xD;
&#xD;
          -  MDS occurring in patients with Fanconi anemia or congenital dyskeratosis&#xD;
&#xD;
          -  Proliferative disease in patients not in remission: White Blood Cell (WBC) &gt; 15 G/L or&#xD;
             use of continuous cytotoxic to maintain WBC &lt; 15 G/L&#xD;
&#xD;
          -  AML with marrow or peripheral blast count higher than 10% after chemotherapy&#xD;
&#xD;
          -  Known allergy or hypersensitivity to the investigational agent or decitabine or its&#xD;
             metabolites or formulation excipients&#xD;
&#xD;
          -  No contraception&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie ROBIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Louis - Service hématologie-greffe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre FENAUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Louis - Service hématologie séniors</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie ROBIN, MD</last_name>
    <phone>+33 142499660</phone>
    <email>marie.robin@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatiha CHERMAT</last_name>
    <phone>+33 171207059</phone>
    <email>fatiha.chermat-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Angers - Service des maladies du sang</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain THEPOT, MD</last_name>
      <phone>+33 241354475</phone>
      <email>sylvain.thepot@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain THEPOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing - Service hématologie clinique et thérapie cellulaire</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélie RAVINET, MD</last_name>
      <phone>+33 473700066</phone>
      <email>aravinet@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Aurélie RAVINET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Clinique Universitaire d'hématologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie PARK, MD</last_name>
      <phone>+33 476766277</phone>
      <email>spark@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie PARK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Limoges - Hôpital Dupuytren - Service hématologie clinique et thérapie cellulaire</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal TURLURE, MD</last_name>
      <phone>+33 555058039</phone>
      <email>pascal.turlure@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal TURLURE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu - Service hématologie clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice CHEVALLIER, MD</last_name>
      <phone>+33 240083994</phone>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice CHEVALLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - Service hématologie-greffe</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie ROBIN, MD</last_name>
      <phone>+33 142499660</phone>
      <email>marie.robin@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie ROBIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière - Service hématologie clinique</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie NGUYEN-QUOC, MD</last_name>
      <phone>+33 142162825</phone>
      <email>stephanie.nguyen-quoc@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie NGUYEN-QUOC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker - Service hématologie adulte</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felipe SUAREZ, MD</last_name>
      <phone>+33 144495368</phone>
      <email>felipe.suarez@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Felipe SUAREZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Haut-Lévèque de Bordeaux - Service des maladies du sang</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edouard FORCADE, MD</last_name>
      <phone>+33 557656727</phone>
      <email>edouard.forcade@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Edouard FORCADE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud - Servide Hématologie</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69645</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène LABUSSIERE-WALLET, MD</last_name>
      <phone>+33 478862205</phone>
      <email>helene.labussiere-wallet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène LABUSSIERE-WALLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel - Département d'hématologie</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
      <phone>+33 232082946</phone>
      <email>aspasia.stamatoullas@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth - Hématologie clinique et thérapie cellulaire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline LEJEUNE, MD</last_name>
      <phone>+33 477917061</phone>
      <email>caroline.lejeune@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline LEJEUNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole - Département d'hématologie - Service de greffe de cellules souches hématopoïétiques</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne HUYNH, MD</last_name>
      <phone>+33 531156191</phone>
      <email>huynh.anne@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Anne HUYNH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brabois - Service hématologie clinique</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maud D'AVENI, MD</last_name>
      <phone>+33 383153030</phone>
      <email>m.daveni-piney@chru-nancy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Agnès GUERCI-BRESLER, MD</last_name>
      <phone>+33 383153281</phone>
      <email>a.guerci@chru-nancy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Maud D'AVENI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnès GUERCI-BRESLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Very high risk MDS</keyword>
  <keyword>AML</keyword>
  <keyword>ASTX727</keyword>
  <keyword>DLI</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

